CareFirst
The CareFirst BlueCross BlueShield family of health care plans

CVS/caremark

Zykadia (for Maryland only)

Prior Authorization Request

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

1. What is the patient's diagnosis?
   - ❑ Non-small cell lung cancer (NSCLC)
   - ❑ Inflammatory myofibroblastic tumor (IMT)
   - ❑ Other _____
2. What is the ICD-10 code? _____
3. Would the prescriber like to request an override of the step therapy requirement? ❑ Yes ❑ No *If No, skip to #6*
4. Has the member received the medication through a pharmacy or medical benefit within the past 180 days? ❑ Yes ❑ No ***ACTION REQUIRED: Please provide documentation to substantiate the member had a prescription paid for within the past 180 days (i.e. PBM medication history, pharmacy receipt, EOB etc.)***
5. Is the medication effective in treating the member's condition? ❑ Yes ❑ No *Continue to #6 and complete this form in its entirety.*
6. Is the tumor anaplastic lymphoma kinase (ALK)-positive? ❑ Yes ❑ No ❑ Unknown
   ACTION REQUIRED: Attach test results of ALK gene rearrangements.

Complete the following section based on the patient's diagnosis, if applicable.

Section A: Non-Small Cell Lung Cancer (NSCLC)

7. Does the patient have recurrent or metastatic disease? ❑ Yes ❑ No
8. What agents (if any) has the patient experienced disease progression on?
   - ❑ crizotinib (Xalkori), *no further questions*
   - ❑ Other _____
   - ❑ None
9. Has the patient experienced intolerance to crizotinib (Xalkori)? ❑ Yes ❑ No

Section B: Inflammatory Myofibroblastic Tumor (IMT)

10. Will Zykadia be used as a single agent? ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**